Mammalian Or Microbial? Considerations When Choosing An Expression System For Your Product

Biologics have emerged as a revolutionary therapeutic modality, offering hope to patients suffering from previously untreatable diseases. These targeted therapies are made possible through the development of biological drug substances, which come in a variety of molecules with different structures and characteristics. The production of these substances relies on either mammalian or microbial expression systems.

Traditionally, mammalian cells have been the go-to choice for a wide range of applications. However, recent advancements in microbial fermentation have made both systems viable options for producing biologics. Choosing the right expression system is crucial, as each system has its own advantages and challenges.

When it comes to clone selection, microbial systems like E. coli and pichia pastoris offer simplicity and speed. On the other hand, mammalian cells, particularly CHO cells, are better suited for products requiring glycosylation. Fermentation process development is typically faster and less complex in microbial systems, while mammalian systems tend to yield higher product quantities.

Factors such as oxygen transfer, mixing, reactor design, and impeller type also come into play when optimizing and scaling up the process. Microbial platforms are known for their cost-effectiveness and speed, but they do have lower yields. Mammalian platforms, on the other hand, offer higher yields but require more extensive cell line screening.

Ultimately, the choice between microbial and mammalian expression systems depends on the specific product and its requirements. Discover how whether you’re trying to achieve speed and cost-effectiveness or higher yields and glycosylation capabilities, the right system can be tailored to meet the needs of each unique biologic.